We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ARWR market cap is 3.09B. The company's latest EPS is USD -1.6568 and P/E is -15.03.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 146.27M | 15.83M | 16.1M | 3.55M | 0 |
| Operating Income | 48.17M | -102.7M | -108.33M | -136.55M | -126.19M |
| Net Income | 48.68M | -102.95M | -109.68M | -132.86M | -125.3M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 168.8M | 87.99M | 138.29M | 243.23M | 240.74M |
| Operating Income | 61.19M | -93.16M | -149.04M | -178.51M | -205M |
| Net Income | 67.98M | -84.55M | -140.85M | -176.06M | -205.28M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 891.31M | 795.86M | 765.55M | 626.29M | 955.15M |
| Total Liabilities | 426.2M | 413.87M | 478.39M | 452.57M | 459.75M |
| Total Equity | 465.11M | 381.99M | 287.16M | 173.71M | 495.41M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 349.85M | 522.5M | 710.15M | 691.94M | 765.55M |
| Total Liabilities | 105.81M | 60.73M | 301.33M | 273.6M | 478.39M |
| Total Equity | 244.04M | 461.78M | 408.82M | 418.34M | 287.16M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -107.19M | -128.63M | -153.89M | -117.84M | -210.22M |
| Investing | -116.76M | -126.66M | -96.16M | 64.84M | -204.1M |
| Financing | 251.1M | 252.9M | 253.05M | 267k | 431.04M |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 173.04M | -95.39M | 171.22M | -136.13M | -153.89M |
| Investing | -47.75M | -240.78M | -141.68M | -5.42M | -96.16M |
| Financing | 66.38M | 257.95M | 11.31M | 65.19M | 253.05M |
| Market Cap | 3.09B |
| Price to Earnings Ratio | -15.03 |
| Price to Sales Ratio | 12.82 |
| Price to Cash Ratio | 29.95 |
| Price to Book Ratio | 10.74 |
| Dividend Yield | - |
| Shares Outstanding | 123.9M |
| Average Volume (1 week) | 1.08M |
| Average Volume (1 Month) | 1.05M |
| 52 Week Change | -29.84% |
| 52 Week High | 39.83 |
| 52 Week Low | 20.67 |
| Spread (Intraday) | 0.06 (0.24%) |
| Company Name | Arrowhead Pharmaceuticals Inc |
| Address |
2140 south dupont highway camden, delaware 19934 |
| Website | https://www.arrowheadpharma.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
